Chemotherapy and Radiotherapy for Osteolymphoma

Trans Tasman Radiation Oncology Group

Status: Completed

Conditions: Osteolymphoma

Treatments: Drug: Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.; Radiation: Radiotherapy

Study type: Interventional

Funder types: Other

Identifiers

NCT00141648

TROG 99.04

ALLG LY-02

Details and patient eligibility

About

This trial is intended to determine the results obtained when standard treatment for Non Hodgkin's lymphoma is applied to the disease in a rare subtype which arises in bone. Patients in the study undergo a detailed assessment, then treatment with chemotherapy and radiotherapy, followed by close monitoring.

Full description

Patients with non-Hodgkin's lymphoma arising primarily in bone have been studied using a number of different names making literature searching difficult. The term Osteolymphoma has been proposed to make searching easier in the future. Patients in this study undergoing staging which includes isotope bone scanning and PET scanning where available. Eligible patients then undergo treatment with three cycles of CHOP chemotherapy at conventional doses and shrinking field radiotherapy to a total of 45 Gy. Monoclonal antibodies are not included as good results have been obtained without using them. After treatment the patients are regularly monitored. The trial is presented twice per year at the meetings of TROG, ALLG and AROLG.

Enrollment: 70 patients

Sex: All

Ages: 17+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed non-Hodgkin's lymphoma in a bony site
• Limited extraosseous disease
• Ann Arbor stage IE
• Age >17
• ECOG performance status <3
• Expected survival > 6 months
• Patients capable of childbearing are using adequate contraception.
• Written informed consent

Exclusion criteria

• Previous radiotherapy
• Previous malignancy
• Medically unfit to undergo treatment

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

70 participants in 1 patient group

1

Experimental group

Description:

Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.

Treatment:

Radiation: Radiotherapy

Drug: Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.